论文部分内容阅读
目的:通过比较二甲双胍在晚期乳腺癌伴糖尿病患者中能否提高其新辅助化疗的疗效,探讨二甲双胍的抗肿瘤作用。方法:回顾性分析2013年5月-2017年3月于我院行新辅助化疗的225例初治的乳腺癌患者。结果:二甲双胍糖尿病组、未使用二甲双胍糖尿病组、未患糖尿病组的总有效率(CR+PR)分别为64%,29%,45%。二甲双胍糖尿病组患者新辅助化疗总有效率(CR+PR)高于未使用二甲双胍糖尿病组的患者,差异有统计学意义(P=0.007)。结论:在晚期乳腺癌伴糖尿病患者中,使用二甲双胍者较未使用者新辅助化疗的有效率更高。
Objective: To compare whether metformin can improve the efficacy of neoadjuvant chemotherapy in patients with advanced breast cancer and to explore the anti-tumor effect of metformin. Methods: A retrospective analysis of 225 patients with newly diagnosed breast cancer receiving neoadjuvant chemotherapy in our hospital from May 2013 to March 2017 was retrospectively analyzed. Results: The total effective rate (CR + PR) in metformin diabetic patients without metformin and without diabetes was 64%, 29% and 45%, respectively. The total effective rate of neoadjuvant chemotherapy (CR + PR) in patients with metformin diabetes was significantly higher than that of patients without metformin diabetes (P = 0.007). Conclusions: Metformin is more effective than neoadjuvant chemotherapy in patients with advanced breast cancer and diabetes mellitus.